论文部分内容阅读
目的探讨金天格胶囊联合雌激素治疗对绝经后骨质疏松患者骨密度和骨代谢的影响。方法收集2012年1月-2015年1月台州市中医院收治的100例绝经后骨质疏松患者,将患者随机分为研究组和对照组,每组各50例。研究组采用金天格胶囊联合雌激素治疗,对照组仅采用雌激素治疗。观察两组患者股骨颈骨密度和骨代谢相关指标(降钙素、磷、钙、碱性磷酸酶、骨钙素、抗酒石酸酸性磷酸酶5b、转化生长因子-β1和Ⅰ型胶原羧基末端肽)。结果与治疗前比较,治疗后6个月和12个月两组患者骨密度明显增加(P<0.05)。两组患者治疗前骨密度比较,差异无统计学意义[(0.54±0.05)g/cm~2vs.(0.55±0.06)g/cm~2,P=0.497]。与对照组比较,研究组治疗后6个月骨密度显著增加[(0.67±0.09)g/cm~2vs.(0.57±0.07)g/cm~2,P=0.000)];治疗12个月后骨密度显著增加[(0.70±0.10)g/cm~2vs.(0.62±0.09)g/cm~2,P=0.000]。两组患者治疗前降钙素、骨钙素和抗酒石酸酸性磷酸酶5b水平比较,差异无统计学意义(P>0.05)。与对照组比较,治疗后12个月研究组降钙素显著增加[(262.83±72.72)pg/ml vs.(231.81±62.48)pg/ml,P=0.041)];骨钙素显著增加[(11.53±2.69)μg/L vs.(9.35±2.27)μg/L,P=0.000];抗酒石酸酸性磷酸酶5b显著降低[(3.52±0.92)m IU/ml vs.(4.52±1.04)m IU/ml,P=0.000)]。治疗前后两组患者血清磷、钙离子、转化生长因子-β1和Ⅰ型胶原羧基末端肽水平比较,差异均无统计学意义(P>0.05)。结论金天格胶囊联合雌激素治疗有助于改善绝经后骨质疏松患者骨密度和骨代谢指标。
Objective To investigate the effect of Jintiange capsule combined with estrogen therapy on bone mineral density and bone metabolism in postmenopausal osteoporosis patients. Methods A total of 100 patients with postmenopausal osteoporosis who were treated in Taizhou Hospital of Traditional Chinese Medicine from January 2012 to January 2015 were collected and randomly divided into study group and control group with 50 cases in each group. The study group treated with Jintiange capsule combined with estrogen, the control group only treated with estrogen. The femoral neck bone mineral density and bone metabolism-related indicators (calcitonin, phosphorus, calcium, alkaline phosphatase, osteocalcin, tartrate-resistant acid phosphatase 5b, transforming growth factor-β1 and collagen type I carboxyterminal peptide ). Results Compared with those before treatment, the bone mineral density of the two groups increased significantly (P <0.05) at 6 and 12 months after treatment. There was no significant difference in BMD between the two groups before treatment [(0.54 ± 0.05) g / cm ~ 2 vs (0.55 ± 0.06) g / cm ~ 2, P = 0.497]. Compared with the control group, the BMD of the study group increased significantly at 6 months after treatment ([(0.67 ± 0.09) g / cm 2 vs 0.57 ± 0.07 g / cm 2, P = 0.000) BMD increased significantly ([0.70 ± 0.10] g / cm ~ 2vs. (0.62 ± 0.09) g / cm ~ 2, P = 0.000]. The two groups of patients before treatment calcitonin, osteocalcin and tartrate acid phosphatase 5b levels, the difference was not statistically significant (P> 0.05). Compared with the control group, calcitonin significantly increased in the study group at 12 months after treatment (262.83 ± 72.72 pg / ml vs. 231.81 ± 62.48 pg / ml, P = 0.041) 11.53 ± 2.69) μg / L vs. (9.35 ± 2.27) μg / L, P = 0.000]; tartrate-resistant acid phosphatase 5b was significantly reduced [(3.52 ± 0.92) m IU / ml vs. (4.52 ± 1.04) / ml, P = 0.000)]. There were no significant differences in the levels of serum P, Ca2 +, TGF-β1 and type Ⅰ collagen carboxyterminal peptide between the two groups before and after treatment (P> 0.05). Conclusion Jintiange capsule combined with estrogen therapy can improve the bone mineral density and bone metabolism in postmenopausal osteoporosis patients.